Cancer Clinical Investigator Team Leadership Award (CCITLA)



Cancer Clinical Investigator Team Leadership Awards

- Recognize and support outstanding clinical investigators at NCIdesignated Cancer Centers who are actively engaged in NCI-funded collaborative clinical trials
- Promote the retention of clinical investigators in academic clinical research careers

Overview

- Competitive award; candidates nominated annually by NCI Cancer
 Center Directors
- 8 to 12 new awards per year
- \$60,000 per year for 2 years
- At least 15% effort; time protected by sponsoring institution
- 96% of recipients who have completed award (n=124, 2009-2019) are still in academic clinical research positions

Supported Activities

- Include, but not limited to:
 - Engaging fellows and new faculty in collaborative clinical research efforts
 - Organizing courses, lecture/seminar series, educational sessions, workshops related to clinical trials
 - Participating on cancer center committees related to clinical trials
 - Developing clinical trial(s)
 - Designing and implementing initiatives to better coordinate, support and integrate clinical trials efforts at the institution
 - Efforts to improve access, accrual and efficiency of clinical trials

Eligibility

- Practicing at least 3 years but no more than 8 years post-fellowship
- Currently practicing in the oncology clinical setting; board certified
- Full-time faculty member, assistant or associate professor level
- Engaged in conducting NCI-funded cancer clinical trials
- Physician or oncology nurse, clinical psychologist, or similarly qualified clinician with a doctoral degree

Evaluation Criteria

- Training and experience
- Leadership experience in clinical research activities/clinical trials
- Extent of participation in clinical trials and related activities
- Nominee's planned activities to promote a successful clinical research culture at his/her institution
- Institutional commitment to allow at least 15% effort for proposed activities
- Institutional commitment to the career development of the nominee

CCITLA Program

- First awards made in 2009
- 143 recipients through 2021



2021 Recipients' Disease Focus Areas

- Breast cancer
- Gastrointestinal cancer
- Genitourinary cancer
- Gynecologic cancer
- Melanoma
- Pediatric and adult brain cancer



Brian Christopher Baumann, MD

Washington University, Siteman Cancer
Center

Radiation Oncology/GU Malignancies



Daniel V. T. Catenacci, MD, MS

University of Chicago Comprehensive Cancer Center

Medical Oncology/GI Malignancies





Kristen K. Ciombor, MD, MSCI

Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center

Medical Oncology/GI Malignancies



Bree Ruppert Eaton, MD

Emory University, Winship Cancer Institute

Radiation Oncology/Pediatric & Adult Brain Malignancies



Zeynep Eroglu, MD

University of South Florida, H. Lee Moffitt Cancer Center & Research Institute

Medical Oncology/GU Malignancies



Joseph W. Kim, MD

Yale Cancer Center

Medical Oncology/GU Malignancies



Mark V. Mishra, MD

University of Maryland, Marlene & Stewart Greenebaum Comprehensive Cancer Center

Radiation Oncology/GU & CNS Malignancies



Zahi Ibrahim Mitri, MD, MS

Oregon Health Science University, Knight Cancer Institute

Medical Oncology/Breast Malignancies



Alison M. Schram, MD

Memorial Sloan Kettering Cancer Center

Medical Oncology/ Gynecologic

Malignancies



Nataliya V. Uboha, MD, PhD

University of Wisconsin, Carbone
Cancer Center

Medical Oncology/GI Malignancies

Congratulations to the 2021 NCI Cancer Clinical Investigator Team Leadership Award Recipients



R50 Clinical Scientist and Future CCITLA Programs

R50 Clinical Scientist Research Award: Purpose

 Provide a career path and stable salary support for outstanding clinician scientists who want to focus on the design and conduct of NCI-funded clinical trials, but not seek independent research funding


Background

- Outstanding clinical investigators at academic institutions carry out activities that are critical to the success of NCI clinical trials
- Research activities include accruing patients, developing national trials, and providing leadership for the clinical trials infrastructure of institutions
- Clinical duties and requirements to generate clinical revenue make it difficult for clinician investigators to dedicate the necessary time to clinical research activities
- Encouraging a career path in academia with stable funding is vital to retaining these clinician scientists

Portfolio Analysis

- There are no mechanisms currently offered by NCI that provide a clinical career path with sustained salary support
- Related mechanisms:
 - Cancer Clinical Investigator Team Leadership Award (CCITLA)
 - P30 Developmental Funds Clinical Staff Investigator
 - K12 and K08 Early-stage clinician scientist mentored research training
- Research Specialist R50 award mechanisms are for laboratory-based scientists

NCI Grant Funding for Clinician Scientists



*CCITLA switch towards earlier stage

CD=Career Development; DF=Developmental Funds



CCITLA Current Program

- Provides recognition and limited support for outstanding mid-career clinical investigators at NCI-designated Cancer Centers who are actively engaged in NCI-funded collaborative clinical trials
- Administrative supplement to P30 grant; not individual award
- ~ 15% effort (\$60,000 per year for 2 years); non-renewable
- 8 to 12 awards per year

Proposed R50 Clinical Scientist Award

- Provides a <u>career path</u> and <u>stable salary support</u> for outstanding clinician scientists to focus on the design and conduct of NCI-funded clinical trials but who do not seek independent research funding
- Individual grant award
- 20 to 40% effort
- 5-year award; renewable
- 25 awards in the first-year

Next Steps

- R50 NCI Research Specialist (Clinician Scientist) Award
 - Concept approved by BSA
 - Funding Announcement in development; targeted release Fall 2021
- Clinical Investigator Team Leadership Award (CCITLA)
 - Plan to seek CTAC input on modification of applicant eligibility criteria after release of R50 Funding Announcement
 - Modifications under consideration:
 - Focus on more junior investigators, assistant professor only
 - Support underrepresented oncologists involved in NCI supported clinical trials

NOTHING WILL STOP US STOP US STOP US STOP US STOP US STOP STOP IN THE PROPERTY OF THE PROPERTY